Supporting Document Results of Six Month Follow-Up
Electronic Supplementary Material
Appendix Table 1: Multivariate logistic regression results
Variable / Coefficient ± SE / p-valueConstant / -1.254 ± 0.241 / <0.001
Age / -0.028 ± 0.004 / <0.001
Male / 0.009 ± 0.114 / 0.940
Obese / 0.032 ± 0.116 / 0.783
PASI ≥ 10 / 1.922 ± 0.159 / <0.001
DLQI ≥ 10 / 0.678 ± 0.154 / <0.001
PASI ≥ 10 & DLQI ≥ 10 a / 2.403 ± 0.145 / <0.001
Psoriasis arthritis / 0.609 ± 0.119 / <0.001
Nail psoriasis / -0.025 ± 0.127 / 0.844
Non-palm pustular / -0.417 ± 0.273 / 0.126
Palm pustular / -0.237 ± 0.376 / 0.529
General pustular / 0.668 ± 0.500 / 0.182
Erythroderma / 0.264 ± 0.371 / 0.477
Acrodermatitis / 1.007 ± 0.588 / 0.087
Provider type
Non-university hospital / (reference group)
University hospital / -0.267 ± 0.129 / 0.038
Individual practice / -0.060 ± 0.137 / 0.660
Observations / 3,165
LR test statistic / 529.09 ***
Pseudo / 0.191
McFadden’s adjusted / 0.191
Note: * p < 0.1; ** p < 0.05; *** p < 0.01
PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index; LR, likelihood ratio; SE, standard error
a The marginal effect of the interaction term PASI ≥ 10 and DLQI ≥ 10 is captured within the variables PASI ≥ 10 and DLQI ≥ 10. The interaction term is therefore not included in Table 3
Supporting document – Results of six month follow-up
Table 4: The proportion of patients who fulfilled the criteria for moderate-to-severe psoriasis (PASI ≥ 10 and DLQI ≥ 10) in patients who switched to biologics and in patients who remained on conventional systemic treatment
Non-university hospital, n(%) / University hospital, n(%) / Individual practice, n(%) / All providers, n(%)Switch to biologics / PASI ≥ 10 and DLQI ≥ 10 a / 90 (8) / 53 (5) / 27 (3) / 170 (5)
PASI < 10 and/or DLQI < 10 b / 124 (10) / 105 (10) / 103 (12) / 332 (10)
No switch to biologics / PASI ≥ 10 and DLQI ≥ 10 a / 90 (8) / 73 (7) / 44 (5) / 207 (7)
PASI < 10 and/or DLQI < 10 b / 900 (74) / 836 (78) / 720 (80) / 2,456 (78)
Total number of patients / 1,204 (100) / 1,067 (100) / 894 (100) / 3,165 (100)
a Patients who fulfilled the criteria at last contact before switch
b Patients not observed to fulfil the criteria at last contact
PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index
Table 5: Average marginal effect (AME) of patient-related covariates and provider type
Variable / AME / p-value / 95% CIAge / -0.003 ± <0.001 / <0.001 / -0.004 to -0.002
Male / -0.002 ± 0.012 / 0.878 / -0.022 to 0.026
Obese / 0.004 ± 0.013 / 0.756 / -0.021 to 0.029
PASI ≥ 10 / 0.257 ± 0.019 / <0.001 / 0.220 to 0.294
DLQI ≥ 10 / 0.067 ± 0.015 / <0.001 / 0.038 to 0.096
Psoriasis arthritis / 0.066 ± 0.013 / <0.001 / 0.041 to 0.091
Nail psoriasis / -0.006 ± 0.014 / 0.676 / -0.033 to 0.021
Non-palm pustular / -0.046 ± 0.030 / 0.119 / -0.104 to 0.012
Palm pustular / -0.025 ± 0.040 / 0.542 / -0.104 to 0.055
General pustular / 0.073 ± 0.053 / 0.174 / -0.032 to 0.177
Erythroderma / 0.005 ± 0.041 / 0.910 / -0.076 to 0.086
Acrodermatitis / 0.116 ± 0.064 / 0.069 / -0.009 to 0.242
Provider type
Non-university hospital / (reference group)
University hospital / -0.026 ± 0.014 / 0.066 / -0.053 to 0.002
Individual practice / -0.003 ± 0.015 / 0.836 / -0.032 to 0.026
Notes:
PASI, Psoriasis Area and Severity Index; CI, confidence interval;
DLQI, Dermatology Life Quality Index
Appendix Table 2: Multivariate logistic regression results
Variable / Coefficient ± SE / p-valueConstant / -1.337 ± 0.243 / <0.001
Age / -0.027 ± 0.004 / <0.001
Male / 0.018 ± 0.114 / 0.878
Obese / 0.036 ± 0.115 / 0.756
PASI ≥ 10 / 1.919 ± 0.145 / <0.001
DLQI ≥ 10 / 0.720 ± 0.166 / <0.001
PASI ≥ 10 & DLQI ≥ 10 a / 2.324 ± 0.147 / <0.001
Psoriasis arthritis / 0.609 ± 0.119 / <0.001
Nail psoriasis / -0.053 ± 0.126 / 0.676
Non-palm pustular / -0.423 ± 0.271 / 0.119
Palm pustular / -0.226 ± 0.371 / 0.541
General pustular / 0.665 ± 0.490 / 0.175
Erythroderma / 0.043 ± 0.380 / 0.910
Acrodermatitis / 1.068 ± 0.587 / 0.069
Provider type
Non-university hospital / (reference group)
University hospital / -0.236 ± 0.128 / 0.066
Individual practice / -0.028 ± 0.136 / 0.836
Observations / 3,165
LR test statistic / 512.11 ***
Pseudo / 0.185
McFadden’s adjusted / 0.172
Note: * p < 0.1; ** p < 0.05; *** p < 0.01
PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index; LR, likelihood ratio; SE, standard error
a Interaction terms do not have marginal effects since they cannot change independently of their component terms. The interaction variable is therefore not included in Table 3